Free Trial
NASDAQ:PTGX

Protagonist Therapeutics Q2 2025 Earnings Report

Protagonist Therapeutics logo
$51.07 +0.11 (+0.22%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$50.60 -0.48 (-0.93%)
As of 08/8/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Protagonist Therapeutics Revenue Results

Actual Revenue
$5.55 million
Expected Revenue
$8.32 million
Beat/Miss
Missed by -$2.77 million
YoY Revenue Growth
N/A

Protagonist Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:00PM ET

Protagonist Therapeutics Earnings Headlines

Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
Protagonist (PTGX) Q2 Revenue Falls 26%
See More Protagonist Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email.

About Protagonist Therapeutics

Protagonist Therapeutics (NASDAQ:PTGX), a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

View Protagonist Therapeutics Profile

More Earnings Resources from MarketBeat